Save Product
Product Details
Specificity
Specifically recognizes MMAE and does not recognize MMAF.
Source
Monoclonal Anti-MMAE specific Antibody, Rabbit IgG (M1H09) is a Rabbit monoclonal antibody recombinantly expressed from HEK293 cells.
Clone
M1H09
Isotype
Rabbit IgG | Rabbit Kappa
Conjugate
Unconjugated
Immunogen
MMAE-BSA
Application
ApplicationRecommended UsageELISA0.06-125 ng/mLPurification
Protein A purified / Protein G purified
Formulation
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
For best performance, we strongly recommend following the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-ELISA
Immobilized Monoclonal Anti-MMAE specific Antibody, Rabbit IgG (M1H09) (Cat. No. MME-MY2209) at 5 μg/mL, add Disitamab Vedotin (RC48) in the 100% Human Serum and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (QC tested).
Protocol
Immobilized Disitamab Vedotin (RC48) at 0.2 μg/mL (100 μL/well) can bind Monoclonal Anti-MMAE specific Antibody, Rabbit IgG (M1H09) (Cat. No. MME-MY2209) with a linear range of 0.06-1 ng/mL (Routinely tested).
Protocol
Immobilized Monoclonal Anti-MMAE specific Antibody, Rabbit IgG (M1H09) (Cat. No. MME-MY2209) at 5 μg/mL, add Disitamab Vedotin (RC48) in the 0.5% BSA and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (Routinely tested).
Protocol
Serial dilutions of Monomethyl auristatin E were added into Monoclonal Anti-MMAE specific Antibody, Rabbit IgG (M1H09) (Cat. No. MME-MY2209): Disitamab Vedotin (RC48) binding reactions. The half maximal inhibitory concentration (IC50) is 0.007529 μg/mL (Routinely tested).
Protocol
Cross Verification
ELISA binding of Monoclonal Anti-MMAE specific Antibody, Rabbit IgG (M1H09) (Cat. No. MME-MY2209) with Disitamab Vedotin (RC48), Trastuzumab Deruxtecan, Sacituzumab Govitecam, Trastuzumab MMAE and Trastuzumab-DM1 conjugated antibody respectively.
The coating antibody was Monoclonal Anti-MMAE specific Antibody, Rabbit IgG (M1H09) (Cat. No. MME-MY2209), used at 1 μg/mL concentration. The primary antibody were different payload conjugated antibodies, including Disitamab Vedotin (RC48), Trastuzumab Deruxtecan, Sacituzumab Govitecam, Trastuzumab MMAE and Trastuzumab-DM1 conjugated antibodies used at 0.5 μg/mL concentration. The secondary antibody was HRP conjugated Anti-Human-IgG-Fc Antibody (6F11C8), mAb (Acro, Cat. No. IGG-LY69) used at 1:10000 concentration.
Monoclonal Anti-MMAE specific Antibody, Rabbit IgG (M1H09) (Cat. No. MME-MY2209) is specific to Disitamab Vedotin (RC48) and Trastuzumab MMAE, and has no cross-reactivity with Trastuzumab Deruxtecan, Sacituzumab Govitecam and Trastuzumab-DM1 (Routinely tested).
Customer Reviews Writing Reviews
Background
Recent Advances
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
